Cite
HARVARD Citation
Wang, W. et al. (2021). Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC). Bioengineered. 12 (1), pp. 2957-2969. [Online].